The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.
 
Noriko Yanagitani
Consulting or Advisory Role - Chugai Pharma
 
Atsushi Horiike
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer
Research Funding - Chugai Pharma (Inst); MSD Oncology (Inst); Quintiles (Inst)
 
Satoru Kitazono
Speakers' Bureau - Novartis; Pfizer
 
Fumiyoshi Ohyanagi
No Relationships to Disclose
 
Shunsuke Kondo
Research Funding - AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst)
 
Akihiko Shimomura
Research Funding - AstraZeneca
 
Yutaka Fujiwara
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Novartis
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yasutoshi Kuboki
Honoraria - Bayer; Taiho Pharmaceutical
 
Akihito Kawazoe
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Novartis; Takeda
Consulting or Advisory Role - Bayer (Inst); Chugai Pharma (Inst); Lilly (Inst); Takeda (Inst)
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Izumi Ohno
Consulting or Advisory Role - Merck Serono
 
Udai Banerji
Employment - Institute of Cancer Research
Consulting or Advisory Role - Astex Pharmaceuticals; Novartis
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Onyx (Inst)
 
Raghav Sundar
No Relationships to Disclose
 
Shuichi Ohkubo
Employment - Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Taiho Pharmaceutical
 
Jerry M. Huang
Employment - Taiho Pharmaceutical
 
Makoto Nishio
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)